A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer

A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer

Breast cancer (BC) is the most commonly diagnosed cancer globally, with high mortality rates. Targeted drug therapies have revolutionized cancer treatment. For example, treatment with human epidermal receptor 2 (HER2) antagonists has markedly improved the prognosis of patients with HER2-positive BC...

Full description

Bibliographic Details
Main Author:	Moudi M. Alasmari
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Series:	Cancers
Subjects:	margetuximab Fc engineering clinical trials anti-HER2 therapy human epidermal receptor 2 positive metastatic breast cancer
Online Access:	https://www.mdpi.com/2072-6694/15/1/38

Similar Items

Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China
by: Zhiyuan Tang, et al.
Published: (2022-09-01)

Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
by: Marta Tapia, et al.
Published: (2023-09-01)

Male HER-2 positive metastatic breast cancer: A case report
by: Na Lin, et al.
Published: (2020-12-01)

Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer
by: M. A. Frolova, et al.
Published: (2021-12-01)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
by: Bin Shao, et al.
Published: (2022-08-01)

HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments
by: Ismail Essadi, et al.
Published: (2023-03-01)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
by: Salkeni MA, et al.
Published: (2021-09-01)

Real-world experience with trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and HER2-positive gastric cancer: A retrospective study
by: Vladimir I. Evdokimov, et al.
Published: (2023-12-01)

Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature
by: Jennifer Y. Ge, et al.
Published: (2021-07-01)

Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
by: Xiaohui Zhang, et al.
Published: (2021-08-01)

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
by: Shuhui You, et al.
Published: (2023-12-01)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
by: Zihong Wu, et al.
Published: (2023-03-01)

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
by: Simon Peter Gampenrieder, et al.
Published: (2021-12-01)

CLINICAL CASE OF SUCCESFUL APPLICATION OF KADSYLA APPLICATION IN METASTATIC HER2 POSITIVE BREAST CANCER
by: D. D. Sakaeva
Published: (2017-11-01)

First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study
by: Meryem Aitelhaj, et al.
Published: (2016-08-01)

Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies
by: Chiara Tommasi, et al.
Published: (2024-03-01)

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
by: Sung Hoon Sim, et al.
Published: (2022-10-01)

Real-world data of HER2-low metastatic breast cancer: A population based cohort study
by: Emily I. Holthuis, et al.
Published: (2022-12-01)

Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer
by: Shuhui You, et al.
Published: (2023-10-01)

Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003–2015)
by: Benjamin Daniels, et al.
Published: (2019-09-01)

Race Against Time: Addressing the Unmet Needs of Patients with HER2-Positive Metastatic Breast Cancer
by: Katarzyna Rygiel
Published: (2020-11-01)

Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
by: Zhe-Yu Hu, et al.
Published: (2023-06-01)

Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
by: Noortje Verschoor, et al.
Published: (2023-11-01)

Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis
by: Xian-Meng Wu, et al.
Published: (2023-09-01)

HER2-positive breast cancer – Available anti-HER2 therapies and new agents under investigation
by: Martyna Zielińska, et al.
Published: (2020-06-01)

Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
by: Yi Li, et al.
Published: (2020-03-01)

Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
by: Cristiano Ferrario, et al.
Published: (2022-04-01)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
by: Julie Lebert, et al.
Published: (2022-04-01)

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
by: Yi Li, et al.
Published: (2021-04-01)

Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting
by: Sharman Moser S, et al.
Published: (2024-03-01)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
by: Hiromichi Nakajima, et al.
Published: (2022-02-01)

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
by: Chan Arlene, et al.
Published: (2012-11-01)

Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review
by: Ran Ran, et al.
Published: (2022-12-01)

Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends
by: Kreina Sharela Vega Cano, et al.
Published: (2022-12-01)

Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report
by: Fei Qu, et al.
Published: (2023-08-01)

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
by: Claudia Omarini, et al.
Published: (2022-06-01)

Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
by: Francesco Schettini, et al.
Published: (2022-11-01)

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
by: Xiuwen Guan, et al.
Published: (2023-02-01)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
by: Han Y, et al.
Published: (2019-05-01)

Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
by: Angelica Ferrando-Díez, et al.
Published: (2022-07-01)